Fig. 12
Screening of potential small molecule compounds targeting ALG3. A Venn analysis of small molecule compounds targeting ALG3, as predicted by the CTRP and GDSC databases. B–F Visualization of the binding petterns between ALG3 and trametinib (B), selumetinib (C), olaparib (D), etoposide (E), and SN-38 (F) using molecular docking. G 3D structure of selumetinib obtained from the PubChem database. H, I CCK8 assays to assess cell viability after treatment with varying concentrations of selumetinib, with IC50 values calculated. J Western blot analysis of ALG3 expression levels following stimulation with different concentrations of selumetinib (0, 40, 80, 120 μM) for 48 h. K, L CCK8 assays to evaluate changes in cell viability after treatment with selumetinib in combination with ALG3 siRNA transfection in T24 (K) and UMUC3 (L) cells